BiotechTube

neostigmine/glycopyrrolate + sugammadex

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Neuromuscular Blockade

Conditions

Neuromuscular Blockade, Chronic Obstructive Pulmonary Disease

Trial Timeline

Apr 8, 2021 → Jul 30, 2023

NCT ID
NCT04606901

About neostigmine/glycopyrrolate + sugammadex

neostigmine/glycopyrrolate + sugammadex is a approved stage product being developed by Merck for Neuromuscular Blockade. The current trial status is completed. This product is registered under clinical trial identifier NCT04606901. Target conditions include Neuromuscular Blockade, Chronic Obstructive Pulmonary Disease.

What happened to similar drugs?

14 of 20 similar drugs in Neuromuscular Blockade were approved

Approved (14) Terminated (2) Active (6)
✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
✅Deep neuromuscular block + Moderate neuromuscular blockMerckApproved
✅Sugammadex + RocuroniumMerckApproved
✅sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved
🔄sugammadexMerckPhase 3
🔄2 mg/kg sugammadex + 0.07 mg/kg neostigmineMerckPhase 3
✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04606901ApprovedCompleted

Competing Products

20 competing products in Neuromuscular Blockade

See all competitors
ProductCompanyStageHype Score
HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)Jiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + RocuroniumJiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190Jiangsu Hengrui MedicinePhase 2
35
Placebo + Sugammadex + Esmeron®MerckPhase 2
35
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
43
Deep neuromuscular block + Moderate neuromuscular blockMerckApproved
39
Rocuronium + Succinylcholine + Cisatracurium + Mivacurium + Sugammadex + NeostigmineMerckPre-clinical
26
Sugammadex + RocuroniumMerckApproved
43
sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved
43
sugammadexMerckPhase 3
40
2 mg/kg sugammadex + 0.07 mg/kg neostigmineMerckPhase 3
47
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
43
Rocuronium + Sugammadex + Cisatracurium + Neostigmine/Atropine + SuccinylcholineMerckApproved
35
Sugammadex + NeostigmineMerckApproved
43
Sugammadex 2 mg/kg ABW + Sugammadex 2 mg/kg IBW + Sugammadex 4 mg/kg ABW + Sugammadex 4 mg/kg IBW + Neostigmine + Glycopyrrolate + Rocuronium or VecuroniumMerckApproved
43
sugammadex + Neostigmine + GlycopyrrolateMerckApproved
43
Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline + Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;MerckPhase 2
35
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
43
Rocuronium Bromide + Rocuronium BromideMerckApproved
43
Rocuronium (moderate NMB) + Rocuronium (deep NMB)MerckPre-clinical
22